Results 101 to 110 of about 6,036 (190)

One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel

, 2008
Das 30-Tage-Ergebnis der ISAR-REACT-Studie erbrachte keinen klinischen Vorteil durch Abciximab bei Patienten mit perkutaner Koronarimplantation und einer Gabe von 600mg Clopidogrel mindestens zwei Stunden vor dem Eingriff.
Drescher, Andrea
core  

Abciximab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Pharmacovigilance analysis of glycoprotein IIb/IIIa inhibitors: A FAERS-based signal detection study. [PDF]

Medicine (Baltimore)
Huang C, Cao J, Hu X, Xia G, Yan F, Yang X, Cao Z, Huang R, Chen Z.   +8 more
europepmc   +1 more source

Revisiting Antiplatelet Therapy in Acute Carotid Tandem Lesions. [PDF]

J Clin Med
Zupan M, Straus L, Kermer P, Papanagiotou P, Frol S.   +4 more
europepmc   +1 more source

Switch from abciximab to eptifibatide during percutaneous coronary intervention

, 2009
BACKGROUND: Treatment with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) reduce ischemic complications and improve outcome.
Grip, Lars,, Odell, Annika,, Tahmasebiepour, Farshad,, Karlsson, Thomas,, Matejka, Göran,, Albertsson, Per,, Wahlin, Magnus,, Wolmeryd, Christina,   +7 more
core  

Combination of abciximab with primary stenting in patients with acute myocardial infarction: a community hospital experience.

, 2000
Abciximab administration during primary coronary angioplasty in patients with acute myocardial infarction (AMI) reduces death, reinfarction, and the need for urgent target vessel revascularization (TVR).
Arjomand, H, Mascarenhas, D A
core  

Response to letter: "The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing PCI and receiving abciximab". [PDF]

Cardiol J
Altınkaya O, Aydemir S, Özkoç M.
europepmc   +1 more source

Response to the response to the letter: "The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing PCI and receiving abciximab". [PDF]

Cardiol J
Umińska JM.
europepmc   +1 more source

Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).

, 2003
The utility of glycoprotein IIb/IIIa receptor inhibitors as a bail-out modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%
Tcheng, James E, Turco, Mark, Stuckey, Thomas, Grines, Cindy L, Aymong, Eve A, Cox, David A, Stone, Gregg W, Lansky, Alexandra J, Griffin, John J, Guagliumi, Giulio, Ashby, Dale T, Garcia, Eulogio, Mehran, Roxana   +12 more
core  

A Paradoxical Role of ADAMTS13: Enhancing Collagen-Induced Platelet Aggregation and Activation via AKT Phosphorylation. [PDF]

Thromb Haemost
Dong H, Mao Y, Zheng XL.
europepmc   +1 more source